https://simplecast.com Deep Medicine A show from IDEA Pharma. Hosted by Chief Medical Officer, Dr Alexander Gray, this show will focus on deep dives into subjects of interest for the development of more great medicines 2025 IDEA Pharma en Thu, 8 Jun 2023 11:08:11 +0000 Wed, 26 Feb 2025 08:00:12 +0000 https://deep-medicine.simplecast.com Deep Medicine https://image.simplecastcdn.com/images/bc1d3cbd-f08d-4204-9d64-cacf1bd83767/d3454fba-02fd-4f12-9572-6fadf069bbef/3000x3000/screenshot-2022-12-17-at-11-28-37.jpg?aid=rss_feed https://deep-medicine.simplecast.com episodic A show from IDEA Pharma. Hosted by Chief Medical Officer, Dr Alexander Gray, this show will focus on deep dives into subjects of interest for the development of more great medicines IDEA Pharma false https://feeds.simplecast.com/7Q5wUh5G pharmaceutical innovation IDEA Pharma info@ideapharma.com c9308e63-62ee-4682-b5fe-d8c0c7a1939a Deep Medicine | Childhood trauma and the development of adult affective disorders: correlation or causation? Welcome to this episode of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Alex has been joined by Erika Kuzminskaitė, a Doctoral Researcher at the Department of Psychiatry, Amsterdam UMC, Vrije University, Amsterdam Public Health and Amsterdam Neuroscience Research Institutes (https://research.vumc.nl/en/persons/erika-kuzminskaite). Erika has been heavily involved with the Netherlands Study of Depression and Anxiety (NESDA), an ongoing longitudinal cohort study examining the course and consequences of depressive and anxiety disorders in a cohort with a current or remitted depressive and/or anxiety disorder, and a healthy control group.  Alex discussed the complex relationships between different types of childhood trauma and adult affective disorders, and what is known about the neurobiological impact of childhood trauma, and how this might explain the development of adult mental health disorders.

You can find out more about Erika and her work here: 

https://research.vumc.nl/en/persons/erika-kuzminskaite

1.  Penninx BW et al. Int J Methods Psychiatry Res 2008; 17: 121–40

 

A person with blonde hair <p>Description automatically generated with medium confidence" /></p> ]]></description> <pubDate>Thu, 8 Jun 2023 11:08:11 +0000</pubDate> <author>info@ideapharma.com (IDEA Pharma)</author> <link>https://deep-medicine.simplecast.com/episodes/deep-medicine-childhood-trauma-and-the-development-of-adult-affective-disorders-correlation-or-causation-83sx8mgK</link> <content:encoded><![CDATA[<p>Welcome to this episode of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Alex has been joined by Erika Kuzminskaitė, a Doctoral Researcher at the Department of Psychiatry, Amsterdam UMC, Vrije University, Amsterdam Public Health and Amsterdam Neuroscience Research Institutes (<a href=https://research.vumc.nl/en/persons/erika-kuzminskaite). Erika has been heavily involved with the Netherlands Study of Depression and Anxiety (NESDA), an ongoing longitudinal cohort study examining the course and consequences of depressive and anxiety disorders in a cohort with a current or remitted depressive and/or anxiety disorder, and a healthy control group.  Alex discussed the complex relationships between different types of childhood trauma and adult affective disorders, and what is known about the neurobiological impact of childhood trauma, and how this might explain the development of adult mental health disorders.

You can find out more about Erika and her work here: 

https://research.vumc.nl/en/persons/erika-kuzminskaite

1.  Penninx BW et al. Int J Methods Psychiatry Res 2008; 17: 121–40

 

A person with blonde hair <p>Description automatically generated with medium confidence" /></p> ]]></content:encoded> <enclosure length= Deep Medicine | Childhood trauma and the development of adult affective disorders: correlation or causation? IDEA Pharma 00:53:13 Childhood trauma and the development of adult affective disorders: correlation or causation? Childhood trauma and the development of adult affective disorders: correlation or causation? false full 4 472c0e17-347e-4dcc-a50d-6b2fa3c6f9d5 Alzheimer’s of the heart Welcome to this episode of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Alex has been joined by Marie Schroeder, who is a Senior Associate at Novo Seeds (https://novoholdings.dk/novo-seeds/). When this episode was recorded, she was a Principal Scientist at Novo Nordisk in Copenhagen, specializing in heart failure. Marie has spent a significant component of her career examining the role of amyloid in the pathogenesis of cardiomyopathy and is now involved in development programmes for assets aimed at treating patients with hereditary and acquired cardiac amyloidosis, as well as other trials examining cytokine blockade for the management of cardio-renal disease. Alex had a chance to discuss the parallels – and differences – between CNS and cardiac amyloid disease, from both pathologic and therapeutic perspectives.

 

You can find out more about Dr Schroeder and her work here: 

https://www.novonordisk.com/careers/career-areas/research-and-development/cvd-researchers.html

 

]]> Fri, 5 May 2023 12:05:27 +0000 info@ideapharma.com (Marie Schroeder, Alex Gray) https://deep-medicine.simplecast.com/episodes/alzheimers-of-the-heart-NHRrgEIK Welcome to this episode of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Alex has been joined by Marie Schroeder, who is a Senior Associate at Novo Seeds (https://novoholdings.dk/novo-seeds/). When this episode was recorded, she was a Principal Scientist at Novo Nordisk in Copenhagen, specializing in heart failure. Marie has spent a significant component of her career examining the role of amyloid in the pathogenesis of cardiomyopathy and is now involved in development programmes for assets aimed at treating patients with hereditary and acquired cardiac amyloidosis, as well as other trials examining cytokine blockade for the management of cardio-renal disease. Alex had a chance to discuss the parallels – and differences – between CNS and cardiac amyloid disease, from both pathologic and therapeutic perspectives.

 

You can find out more about Dr Schroeder and her work here: 

https://www.novonordisk.com/careers/career-areas/research-and-development/cvd-researchers.html

 

]]> Alzheimer’s of the heart Marie Schroeder, Alex Gray 00:43:25 Unraveling the role of amyloid in cardiomyopathy Unraveling the role of amyloid in cardiomyopathy false full 3 4aa5adc3-e356-43b8-857c-00eaf4a00ded Deep Medicine | Avoiding the needle: how new imaging techniques are transforming prostate cancer detection You can find out more about Professor Emberton and his work here: https://iris.ucl.ac.uk/iris/browse/profile?upi=MEMBE52

]]> Thu, 9 Feb 2023 14:56:24 +0000 info@ideapharma.com (IDEA Pharma) https://deep-medicine.simplecast.com/episodes/deep-medicine-avoiding-the-needle-how-new-imaging-techniques-are-transforming-prostate-cancer-detection-ydcRUsFI You can find out more about Professor Emberton and his work here: https://iris.ucl.ac.uk/iris/browse/profile?upi=MEMBE52

]]> Deep Medicine | Avoiding the needle: how new imaging techniques are transforming prostate cancer detection IDEA Pharma 00:56:50 Welcome to this, the second in the series of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Today Alex has been joined by Mark Emberton, Dean, Faculty of Medical Sciences, University College London, Professor of Interventional Oncology, Division of Surgery and Interventional Science, UCL, and an Honorary Consultant Urologist at University College London Hospitals NHS Trust. Mark has been at the forefront of imaging techniques for early prostate cancer detection, changing the detection paradigm in UK (and beyond) through his pioneering work with MRI. He has also driven the practice of minimally-invasive treatment techniques such as HIFU for early prostate cancer treatment. Alex had a chance to discuss state-of-the-art in early detection with Mark, and consider where future data might lead us in better detecting, categorizing, and managing early prostate cancer. Welcome to this, the second in the series of Deep Medicine, with your Host Alexander Gray: the Chief Medical Officer of IDEA Pharma. Today Alex has been joined by Mark Emberton, Dean, Faculty of Medical Sciences, University College London, Professor of Interventional Oncology, Division of Surgery and Interventional Science, UCL, and an Honorary Consultant Urologist at University College London Hospitals NHS Trust. Mark has been at the forefront of imaging techniques for early prostate cancer detection, changing the detection paradigm in UK (and beyond) through his pioneering work with MRI. He has also driven the practice of minimally-invasive treatment techniques such as HIFU for early prostate cancer treatment. Alex had a chance to discuss state-of-the-art in early detection with Mark, and consider where future data might lead us in better detecting, categorizing, and managing early prostate cancer. false full 2 818c58fd-200c-4421-afff-d22074861098 Deep Medicine | Different origins of cognitive impairment: implications for behavioural and pharmacologic intervention You can find out more about Professor Leff and his work here: https://www.ucl.ac.uk/icn/people/alex-leff

]]> Fri, 30 Dec 2022 12:34:09 +0000 info@ideapharma.com (IDEA Pharma) https://deep-medicine.simplecast.com/episodes/deep-medicine-different-origins-of-cognitive-impairment-implications-for-behavioural-and-pharmacologic-intervention-htpKp4mD You can find out more about Professor Leff and his work here: https://www.ucl.ac.uk/icn/people/alex-leff

]]> Deep Medicine | Different origins of cognitive impairment: implications for behavioural and pharmacologic intervention IDEA Pharma 00:51:26 Welcome to this, the first in the series of Deep Medicine, with your host Dr Alexander Gray, the Chief Medical Officer of IDEA Pharma. Today Alex has been joined by Alexander Leff, Professor of Cognitive Neurology and Consultant Neurologist, Department of Brain Repair and Rehabilitation, at the Institute of Neurology, University College London, London, UK. Professor Leff is a pioneer in the field of cognitive rehabilitation. Alex had a chance to discuss with him the differences he sees between cognitive deficits in psychiatric conditions versus those in people who have had a stroke, and discuss the boundaries between behavioural approaches and potential pharmacologic strategies in managing patients with different types of cognitive impairment. Welcome to this, the first in the series of Deep Medicine, with your host Dr Alexander Gray, the Chief Medical Officer of IDEA Pharma. Today Alex has been joined by Alexander Leff, Professor of Cognitive Neurology and Consultant Neurologist, Department of Brain Repair and Rehabilitation, at the Institute of Neurology, University College London, London, UK. Professor Leff is a pioneer in the field of cognitive rehabilitation. Alex had a chance to discuss with him the differences he sees between cognitive deficits in psychiatric conditions versus those in people who have had a stroke, and discuss the boundaries between behavioural approaches and potential pharmacologic strategies in managing patients with different types of cognitive impairment. false full 1